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ABSTRACT 
.T-cell reeonstitution following allogeneic stem cell transplantation may involve thymic education of donor-derived 
precursors or peripheral expansion of mature T cells transferred in the graft. T ceil-receptor excision circles 
(sjTRECs) are generated within the thymus and identify new thymic emigrants and those that have not divided. We 
measured quantitative and qualitative immunologic reconstitution and sjTREC levels in adult and pediatric recipi- 
ents of umbilical cord blood transplants (UCBTs). sjTRECs were detected at normal evels in all children, starting 
12 months after transplantation, sjTRECs were not detected until 18 months after transplantation in adults, and 
then only at a 3-fold lower level than expected for age. We used complementarity-determining re ion 3 (CDR3) 
spectratyping to measure changes in T cell-receptor diversity occurring with restoration of thymic function. T-cell 
repertoires were skewed in adults and children at 12 to 18 months after transplantation but recovered to near- 
normal diversity at 2 to 3 years post-UCBT. T-cell repertoires appeared more diverse earlier in children (at 1 to 
2 years post-UCBT) than in adults (at 3 to 4 years post-UCBT). We conclude that early T-cell recovery after 
UCBT occurs primarily through peripheral expansion of adoptively transferred donor T cells and results in skewing 
of the T-cell repertoire. The reappearance of sjTREC-containing cells after UCBT is associated with increasing 
numbers of phenotypically naive T cells, improved mitogen and recall antigen responses, and diversification of the 
T-cell repertoire. The delay in central T-cell recovery in adults relative to children may be due to differences in 
thymic function resulting from age-related atrophy, graft-versus-host disease, or the pharmacologic effects of pro- 
phylaxis and treatment of graft-versus-host disease. 
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INTRODUCTION 
Quantitative and qualitative immunologic reconstitu- 
tion following allogeneic bone marrow transplantation 
(BMT) has been described extensively [1-11], yet the mech- 
anisms by which lymphocytes recover and repopulate the 
immune system remain controversial. Following T-cell 
depletion through high-dose chemotherapy, stem cell 
transplantation (SCT), or human immunodeficiency virus 
(HIV) infection, restoration of the circulating T-cell pool 
may occur through central (thymus-dependent) or periph- 
eral (thymus-independent) mechanisms, or both [12]. Bone 
marrow-derived precursor cells are selected in the thymus 
and can be released into the circulation as naive T cells. 
T cells already in the circulation can expand through a 
process that requires antigen recognition [13]. Experiments 
in euthymic and thymectomized mice demonstrate T-cell 
recovery via both mechanisms, with a bias toward central 
T-cell education as long as the thymus is present [14]. 
Extrathymic T-cell maturation occurring in intestinal 
epithelium has been described [15] but does not appear to 
play a measurable role in recovery of the circulating pool. 
T-cell reconstitution following T cell-depleted allograft 
is prolonged [8,10,11] and is believed to occur primarily 
through peripheral expansion in adults, because the natural 
involution of the thymus with age limits the capacity to edu- 
cate new T cells [16-18]. Expansion of naive and memory 
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cells in the circulating pool requires recognition of specific 
antigen. Because the number of antigens encountered in the 
body after transplantation is limited, only a selected subset of 
available T cells will be expanded, and the resulting reper- 
toire within the circulating pool will be skewed [19]. T cell- 
replete allografts do not appear to be under the same pressure 
to expand, and maintain amore diverse repertoire of antigen 
specificities [6,20]. Infusion of mature donor lymphocytes 
after transplantation can restore repertoire diversity [7,21]. 
However, repertoires may become more skewed if graft- 
versus-host disease (GVHD) develops as a result [22]. 
Umbilical cord blood (UCB) is a potential source of 
hematopoietic stem cells for allogeneic BMT candidates who 
have no related donor. Experience in the pediatric popula- 
tion demonstrates that UCB is more tolerant of HLA mis- 
match than other stem cell sources, resulting in a reduced 
risk of GVHD [23]. At the same time, published series of 
both adult and pediatric patients have shown, by qualitative 
and quantitative measures, a substantial delay in the reconsti- 
tution of cellular immunity and a high risk of infection fol- 
lowing UCB transplantation (UCBT) [24,25] compared with 
that from other hematopoietic cell sources [3,4,8-11]. Cord 
blood T cells appear functionally immature: they have been 
shown to expand slowly in response to antigen stimulation, 
demonstrate a higher threshold for cytokine stimulation, and 
possess a lower effective cytotoxicity relative to adult-donor 
T-cell controls [26-28]. In adults, immune reconstitution 
through both central and peripheral mechanisms may be 
impaired following UCBT. Age-related thymic atrophy may 
preclude central T-cell education. At the same time, func- 
tionally immature cord blood T cells may be deficient in 
their ability to expand in response to antigen and may not be 
able to restore the circulating pool. 
This study was undertaken to determine the mecha- 
nisms by which the circulating T-cell pool is reconstituted 
after UCBT in adults and children. Quantitative and quali- 
tative recovery of the lymphocyte compartments a  defined 
by surface antigen expression (CD4/8, CD45RA/RO, 
CD56, CD19) and proliferative responses to mitogen and 
specific antigen were measured prospectively. Unfortu- 
nately, CD45RA expression does not unequivocally identify 
naive T cells, because they can expand extrathymically with- 
out stimulation [29], and memory (CD45RO +) cells may 
revert back to the naive phenotype [30]. A recently devel- 
oped polymerase chain reaction (PCR)-based assay quanti- 
fies the number of a[3 T cells bearing a circular DNA epi- 
some, the T cell-receptor (TCR) excision circle (sjTREC), 
which results from TCR gene rearrangement exclusively 
within the thymus [31]. As a T cell divides, it replicates the 
recombined TCR gene but not the episomal sjTREC. 
Thus, an increasing concentration of sjTREC DNA in the 
peripheral blood of transplant recipients indicates addition 
of new, thymus-educated T cells from the progenitor pool. 
Naive T-cell counts and proliferative responses to mitogen 
and specific antigen recovered earlier in children (less than 2 
years post-UCBT) than in adults (at least 3 years post- 
UCBT). Quantitative and qualitative immunologic recovery 
followed restoration of sjTREC levels. 
UCBT is complicated by a high rate of infection. To fur- 
ther define the quality of immunologic potential after trans- 
plantation, we examined TCR diversity before and after 
recovery of thymic function. TCR specificity results from 
variability at the complementarity determining regions 
(CDRs), which in turn results from random recombinations 
of single variable (V), joining (l), and constant (C) gene seg- 
ments. Further variability results from nucleotide insertions 
and deletions at the splice between gene segments. CDR3 
spectratyping uses oligonucleotide primers pecific for each of 
25 V gene segments and 1 C gene segment in the TCR[3 
chain to amplify and detect he results of gene rearrange- 
ments that make up CDR3 [32]. The incorporation of indi- 
vidual V[3, J[3, and C[3 segments and variation in the V-J-C 
recombinations determine the TCR repertoire. 
METHODS 
Patients 
A total of 39 adult patients without a suitable HLA- 
matched related or unrelated bone marrow donor underwent 
mismatched unrelated UCBT between February 1995 and 
August 1999 at Duke University Medical Center. Twenty-one 
patients urvived more than 100 days, 3 of whom demon- 
strated autologous recovery. The remaining 18 patients were 
considered in this analysis. Patient characteristics are summa- 
rized in Table t. Eight fully engrafted pediatric patients, 1 to 
6 years posttransplantation, returned for follow-up between 
June 1999 and February 2000 and were chosen at random for 
analysis with the sjTREC and CDR3 spectratype assays. 
These patients erved as the pediatric ohort for comparative 
purposes. All patients were treated following a single phase 1 
protocol approved by the Duke University Medical Center 
Institutional Review Board. Informed consent was obtained 
from each patient or guardian. 
Conditioning 
The 18 adult patients with complete donor engraftment 
and greater than 100-day survival received chemotherapy 
consisting of melphalan 180 mg/m 2over 3 days, melphalan 
135 mg/m 2over 3 days, or cyclophosphamide 120 mg/kg 
over 2 days. Eight of the adults received total body irradia- 
tion (TBI) given as 1350 cGy in 9 fractions of 150 cGy each 
over 5 days, with attenuated dose to the lungs. A further 8 of 
the adults were unable to receive TBI and were given busul- 
fan 16 mg/kg over 4 days with an adjusted ose based on 
serum drug levels. Finally, 2 adult patients with Fanconi 
anemia received thoraco-abdominal irradiation (500 cGy) 
instead of TBI. All 18 adult patients received antithymocyte 
globulin (ATG) at a dose of 75 or 90 mg/m 2over 3 days. 
The 8 pediatric patients received conditioning chemo- 
therapy with melphalan 180 mg/m 2over 3 days, melphalan 
135 mg/m 2over 3 days, or cyclophosphamide 120 mg/kg 
over 2 days. Three of the pediatric patients received fraction- 
ated TBI regimens (1350 cGy given in 9 fractions of 150 cGy 
each over 5 days, with attenuated lung dose). The remaining 
5 pediatric patients could not receive TBI and were given 
busulfan 16 mg/kg over 4 days with an adjusted ose based on 
serum drug levels. As in the adult cohort, all pediatric patients 
received ATG at a dose of 75 or 90 mg/m 2over 3 days. 
GVHD Prophylaxis 
All patients (adult and pediatric) received cyclosporin A
(CYA) for GVHD prophylaxis. Two adult patients received 
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Table I. Characteriytics of Adult and Pediatric Umbilical Cord Blood Transplant Recipients Who Survived More Than I O0 Days After Transplantation* 
Adult  
Total TREC-Assayed Pediatric 
No. of patients 18 I 0 8 
Age, y 29.3 ( I  9.9-58. I)  29.3 ( I  9.9-54.9) 4.6 ( I  .3-17.2) <.00 I 
Weight,  kg 74.7 (43.0-104. I)  70.3(47.4-104. I)  17. I (8.0-84.7) .002 
Diagnosis, n 
AML 5 3 I NS t 
ALL  4 2 4 
CML 3 3 0 
Other  malignant 3 0 I 
Nonmalignant 3 2 2 
HLA matching (in direction of GVH) ,  n 
5 or 6 of 6 antigens 6 4 5 NS 
3 or 4 of 6 antigens 12 6 3 
TBI conditioning, n 
Yes I 0 3 5 NS 
No 8 5 5 
Cell dose 
Mononuclear, xl0T/kg 1.9 (0.65-3.7) 2.1 (0.72-2.7) 3.7 ( I  .0-9.3) .002 
CD34, • I 0S/kg 2.9 (0. I - 16.7) 1.4 (0. I - 12.5) 4.5 (0.6-80.5) NS 
CD3, • 4.2 ( I .  I-8.8) 4.0 ( I .  I-7.9) 9.2 (0-37.9) NS 
T ime to recovery, d 
ANC >500 23 (I  2-37) 25 ( I  2-37) 20 (I 3-30) NS 
Platelet transfusion independent 59 (35-142) 56 (35-135) 60 (34-92) NS 
Acute GVFID, n 
Grade 0-1 I I 8 7 NS 
Grade 2-4 7 2 I 
Chronic GVHD,  n 
Yes 8 6 0 0.0 I 
No 9 4 8 
*Characteristics forboth the population ofall adult patients surviving at least 100 days as a whole and the sub-population fT-cell receptor exci- 
sion circle (TREC)-assayed a ult 100 day survivors are presented. Parameters are expressed asmedian (range) where applicable. There were no 
significant differences between the characteristics of the total adult 100-day survivor group and the TREC-assayed subpopulation, nor were there 
significant differences between TREC-assayed and non-TREC-assayed adult suhpopulations. P values are for differences between the pediatric and 
TREC-assayed adult cohorts. NS indicates not significant; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic 
myeloid leukemia; GVHD, graft-versus-host di ease; TBI, total body irradiation; ANC, absolute neutrophil count. 
tMalignant versus nonmalignant. 
CYA alone, and 2 received CYA with high-dose methylpred- 
nisolone. The remaining 14 adult and all 8 pediatric patients 
received CYA with an intermediate, tapering dose of methyl- 
prednisolone (1mg/kg per day on days 0 through 4, 3 mg/kg 
per day on days 5 through 13, 2 mg/kg per day on days 14 
through 27, then a daily dose tapered by 10% each week). 
CYA was dose-adjusted to maintain serum levels between 
200 and 400 ng/dL. Patients were assessed for GVHD 
according to established criteria [33]. CYA was tapered over 
several months, starting at day 180 in those patients without 
evidence of chronic GVHD. Patients failing or intolerant of 
CYA received tacrolimus (FKS06) instead. 
Immuno log ic  Recovery  
In all adult and pediatric patients, immune recovery was 
analyzed prospectively with quantitative and qualitative 
measures at least every 3 months for the first year after 
transplantation, then annually thereafter. Additional blood 
samples were drawn from adult patients at each of the 
follow-up times, separated by Ficoll, and frozen at -70~ 
following a standard protocol. Peripheral blood was ana- 
lyzed through the hospital clinical aboratory to measure the 
total white blood cell and absolute lymphocyte counts 
(based on an automated or manually interpreted blood 
smear). Donor chimerism was documented by chromosome 
analysis, fluorescence in-situ hybridization for sex chromo- 
somes, or restriction fragment length polymorphism analy- 
sis as appropriate after engraftment. 
Lymphocyte subsets (B, T, memory versus naive T, and 
natural killer [NK] cells) were enumerated using 2-color mul- 
tiparameter flow cytometry. Peripheral blood mononuclear 
cells (PBMCs) were prepared by Ficoll separation of fleshly 
drawn, heparinized whole blood followed by staining with 
fluorescence-labeled monoclonal antibodies. Starting with 
the first patient in February 1995, all samples were stained 
with a standard panel of antibodies, including anti-CD2, 
-CD3, -CD4, -CD8, -CD 16, -CD19, -CD20, -CD10, and 
-CD45. In subsequent years, additional antibodies were 
added to the standard panel, including anti-CD56, -TCR~,  
-TCR~8, -CD45RA, and -CD45RO. Analysis was per- 
formed on a FACScan flow cytometer (Becton Dickinson, 
San Jose, CA). Lymphocyte subset results from 3 adult 
456 
T-Cell Recovery After UCBT 
patients could not be interpreted because the absolute lym- 
phocyte count was not recorded. 
Lymphocyte function was measured as the proliferative 
response of PBMCs to the plant mitogen phytohemagglutinin 
(PHA) and the recall antigen tetanus, following a method pre- 
viously described [34]. Briefly, PBMCs were isolated from 
freshly drawn, heparinized whole blood by Ficoll separation 
and diluted to a concentration f 1 x 106/mE. One hundred 
microliters (1 • 105 PBMCs) was incubated with PHA at 3 dif- 
ferent concentrations for3 to 6 days and with tetanus toxoid at 
4 different concentrations for 6 days. 3H-labeled thymidine 
was added and further incubated for at least 6 hours. 
[3H]thymidine uptake into proliferating PBMCs was meas- 
ured by liquid scintillation counter after harvesting. The best 
responses to mitogen and antigen were recorded. Results 
were compared to unstimulated [3H]thymidine-incubated 
patient control PBMCs (background) and normal volunteer 
donor PBMCs incubated simultaneously. 
sjTREC Measurement 
sjTREC assays were performed retrospectively on all 
available banked samples. The concentration of sjTREC 
DNA in PBMCs was measured by quantitative-competitive 
(QC)-PCR following a method previously described [35]. 
Briefly, DNA was isolated from 2 to 10 million PBMCs 
using the Life Technologies (Rockville, MD) Trizol reagent 
protocol. DNA was resuspended in 100 gL of 8 mmol 
NaOH; the resulting concentration of DNA was deter- 
mined by spectrophotometry. DNA (1 gg) was amplified for 
30 cycles using a 60~ annealing temperature and extension 
at 72~ for 30 seconds in a 50-gL PCR reaction mix con- 
taining lx PCR buffer (Platinum 7~q; Life Technologies), 
1.8 mmol/L MgC12, 200 gmol/L dNTPs, sjTREC Primer A 
(250 nmol/L), sjTREC Primer B (250 nmol/L), 2.5 gCi 
[~32p]dCTP, 0.5 BL Platinum Taq Polymerase (Life Tech- 
nologies), and 5000, 1000, 500, or 100 molecules of sjTREC 
standard (60 base pairs shorter than the target sjTREC 
sequence). PCR products were separated on 6% or 8% 
polyacrylamide g ls. The gels were dried and bands visual- 
ized on a PhosphorImager screen (Molecular Dynamics, 
Sunnyvale, CA) and quantified using ImageQuant (Amer- 
sham Pharmacia Biotech, Piscataway, NJ) software. In this 
assay, the limit of detection was > 100 sjTRECs/Bg DNA. 
CDR3 Spectratyping 
The CDR3 spectratype assay was performed retrospec- 
tively on banked samples. Each spectratype analysis was per- 
formed on a peripheral blood sample that had also been 
assayed for sjTRECs. 
CDR3 spectratyping was performed as previously 
described, with oligonucleotide primers pecific for each of 
23 V[3 gene segments and the C[31 segment [32]. Total 
RNA was extracted from PBMCs using the RNEasy Mini 
Kit (Qiagen, Valencia, CA) or Trizol reagent (Life Tech- 
nologies) and used for first-strand complementary DNA 
(cDNA) synthesis using M-MLV [Moloney murine 
leukemia virus] Reverse Transcriptase (Life Technologies) 
with a random hexamer primer (Promega, Madison, WI). 
cDNA was amplified for 40 cycles by denaturing at 94~ 
for 25 seconds, annealing at 60~ for 45 seconds, and 
extending at 72~ for 40 seconds in a 25-gL PCR reaction 
mix containing lx PCR Buffer C (Invitrogen, Carlsbad, 
CA), 2.5 gmol/L MgC12, 250 gmol/L dNTPs, 2.5 gmol/L 
V[3 primer, 100 Bmol/L C[31 primer, and 0.125 U Ampli- 
Taq DNA polymerase (Applied Biosystems, Foster City, 
CA). The reaction was completed with a final extension at 
72~ for 5 minutes, cDNA derived from cultured Jurkat E6- 
1 (human T-cell leukemia) cells was amplified with the V[38 
primer in a separate r action mixture as a positive control. 
The resulting amplified PCR products were elongated 
over 5 cycles in a run-off reaction with a 5'-6 carboxyfluo- 
rescein (6-FAM)-labeled nested C13t primer and separated 
on a denaturing el. CDR3 size and fluorescence intensity 
were measured using an ABI 377 XL Sequencer, and results 
were analyzed with ABI GeneScan software (version 3.1; 
Applied Biosystems). The number of peaks was counted 
within each V[3 family, and the total fluorescence intensity 
under each peak was calculated across each V[3 family. 
Statistical Analysis 
Where applicable, results were compared (adult versus 
pediatric) to determine significance using the Wilcoxon 
signed-rank test (for continuous data) or the Fisher's exact 
t st (for nominal data). 
RESULTS 
Lymphocyte Subsets 
Lymphocyte subset analyses and proliferation assays 
were performed on 15 of the 18 adult patients with com- 
plete donor engraftment and greater than 100-day survival. 
All but 1 of the 15 patients were documented to be fully 
donor chimeric after transplantation. One patient, who 
received a 6-of-6 HLA-matched and sex-matched cord 
blood unit, was not tested. Mean counts and standard errors 
from the 14 tested patients are shown in Figures 1-3. The 
absolute lymphocyte count remained below normal until the 
2-year follow-up (Figure 1). B cells (defined as CD19 + lym- 
phocytes), on the other hand, recovered quickly after trans- 
plantation and rose to supranormal levels at 1 year. The 
NK cell (defined as CD56 + lymphocytes) count remained 
relatively stable for both adult and pediatric patients 
through 3 years after transplantation, but made up more 
than half of lymphoeytes 3 months after transplantation (not 
shown). The percentage ofNK cells declined over 3 years as 
T-cell (defined as CD3 + lymphocytes) counts recovered. 
T cells remained below normal evels until the 2-year 
follow-up (Figure 2). Further subset analysis howed that 
the CD4 + cells (CD4+CD3 + lymphocytes) remained below 
normal until 2 years posttransplantation, whereas CD8 + 
cells (CD8+CD3 + lymphocytes) rose to the lower limit of 
normal by 1 year. Naive (CD3+CD45RA § and memory 
(CD3+CD45RO +) T-cell populations remained flat through 
2 years but increased sharply at 3 years; however, only 
2 patients were evaluable at 3 years. Memory cells repre- 
sented a larger percentage of the T-cell population (70% 
versus 27%) through the first year after transplantation, 
then declined to the 50% range. 
Lymphocyte subset analysis was performed on all 8 pedi- 
atric patients in the comparison cohort. Normal values for 
children are not well established. Values based on small num- 
bers of healthy children aged 2 years and older (median age 
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F igure  I. Median absolute lymphocyte (A), T cell (CD3 +) (B), B cell (CD19 +) (C), and NK-cell (CD56 +) (D) counts versus time after umbilical cord 
blood transplantation for adult (0) and pediatric ([B) recipients. Vertical bars indicate the 95% confdence intervals. Horizontal dashed lines repre- 
sent the institutional upper and lower limits of normal for adults. Values for the adult and pediatric ohorts have been offset from their correspond- 
ing times for clarity. There were no statistically significant differences between adults and children at the time points examined. The number of 
patients included at each interval appears below each figure. NK indicates natural killer. 
in the pediatric cohort  was 4.6 years) show great range 
between fifth and 95th percentiles [37]. Fifth percentile val- 
ues do not differ substantially from adult lower-limit normal 
values and are not considered independently in this analysis. 
B-cell recovery paralleled that for adults, with a quick rise to 
supranormal levels by the first-year follow-up and remain- 
ing above normal through the 3-year mark. T-cell recovery, 
however, differed strikingly from adults. The absolute T-cell 
count recovered to normal range by 9 to 12 months and 
maintained a steady state. Subset analysis showed rapid and 
sustained recovery of both CD4 + and CD8 § T cells (Figure 
2A and B). As in adults, T cells expressed predominantly the 
memory phenotype (CD3+CD45RO +) 3 months after trans- 
plantation, but shifted in favor of the naive phenotype 
(CD3+CD45RA +) over the next 9 months. This shift was 
marked by a 5-fold rise in naive T-cell number between 9 and 
12 months after transplantation, whereas the memory T-cell 
number barely doubled. 
Statistically significant differences in lymphocyte subset 
counts between adult and pediatric patients were found only 
in CD3+CD4 +, CD3+CD45RO +, and CD3+CD45RA + 
counts, all at 12 months (P values .014, .023, and .0149, 
respectively). 
Lymphocyte Proliferation 
Lymphocyte proliferative responses to PHA (Figure 3A) 
were generally absent at 3 months but improved thereafter 
in the adult cohort. The  responses remained below the 
range of normal controls (control mean _+ 95% confidence 
interval) until the 3-year follow-up. Proliferative responses 
to tetanus were very low through the first 2 years after 
transplantation, but improved somewhat at the 3-year fol- 
low-up (Figure 3B). 
Lymphocyte proliferation assays were performed on all 
8 pediatric patients in the comparison cohort. Proliferative 
responses to PHA essentially paralleled those measured for 
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Figure 2. Median T-celt subset counts after umbilical cord blood transplantation f r adult (@) and pediatric ([Z) recipients: CD4 § (CD4+CD3 +) (A), 
CD8 + (CD8+CD3 +) (B), naive (CD3+CD45RA +)(C), and memory (CD3+CD45RO +)(D). Vertical bars indicate the 95% confidence intervals. Hori- 
zontal dashed lines represent the upper and lower limits of normal for adults [36]. Values for the adult and pediatric ohorts have been offset from 
their corresponding times for clarity. The number of patients included at each interval appears below each figure. Asterisk indicates time point at 
which significant differences were found between adults and children. 
adults, but were higher than adults at all time points. 
Response to tetanus remained low through the first year, but 
improved in the second and third years after transplantation. 
No differences in mitogen or antigen responses between 
adults and children were statistically significant. 
sjTREC Assay 
QC-PCR for sjTREC DNA was performed on 27 sam- 
ples of peripheral blood from 10 adult patients. Twenty-one 
samples were obtained 30 days or more after transplantation 
(median, 3.1 months; range, 1.0 to 5.9 months). Twelve 
assays were performed on 8 patients 100 days or more after 
transplantation. Seven patients had sjTRECs above the 
detection threshold in the peripheral blood (>100 sjTRECs/btg 
PBMC DNA) at a median of 36.0 months (range, 17.5 to 
42 months), with a median 325 TRECs/btg PBMC DNA 
(range, 228 to 728). The median age of patients producing 
TRECs after transplantation was 26.3 years, which would 
predict 1250 TRECs/btg PBMC DNA in normal individu- 
als, following the regression analysis from Patel [35]. The 
sjTREC assay was performed on peripheral blood from all 
8 pediatric patients in the reference cohort at a median of 
30 months (range, 12 to 77 months) after transplantation. 
sjTRECs were assayable in 8 of 9 samples, with a median 
level of 6741 sjTRECs/btg PBMC DNA (range, 157 to 
22,833 sjTRECs/btg PBMC DNA; P = .028 for sjTREC 
positive adults compared with children). Results are pre- 
sented in Figure 4 with estimated age-adjusted normal val- 
ues for the pediatric and adult cohorts. 
CDR3 Spectratyping 
CDR3 spectratyping was performed on 19 samples from 
adult and pediatric patients. Samples included aliquots from 
4 UCB grafts. The remaining 15 samples were obtained 
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Figure 3. Lymphocyte proliferation in response to phytohemagglutinin (PHA) (A), and tetanus (B) after umbilical cord blood transplantation for 
adult (O) and pediatric (D) recipients. Shown are the median fold increases in [3H]thimidine uptake over unstimulated controls. Note the parallel 
delay in responses in the adult patients compared with the phenotype analysis in Figure 2. Vertical bars indicate the 95% confidence intervals. Hori- 
zontal dashed lines represent the lower 95% confidence limits from normal controls. Values for the adult and pediatric ohorts have been offset 
from their corresponding times for clarity. The number of patients included at each interval appears below each figure. There were no statistically 
significant differences between adults and children at the time points examined. 
12 to 77 months after transplantation. The median number 
of peaks identified in each of the UCB grafts was 141 (range, 
121 to 185), consistent with previously published data [38]. 
Spectratyping from- 3 adult samples between 1 and 2 years 
after transplantation demonstrated repertoire skewing: the 
overall number of VI3 families represented and the number 
of peaks within each family were limited, particularly in 
2 patients (Figure 5). T-cel l  repertoires appeared more 
diverse in 3 of 4 adult patients tested 3 years after transplan- 
tation, but remained substantially skewed in 1 patient. In 
contrast, spectratyping from 4 pediatric patients between 1 
and 2 years after transplantation demonstrated diverse reper- 
toires (Figure 6). Fluorescence intensity spectra for each of 
23 V[3 families obtained from 1 adult and 1 pediatric patient 
at 2 different ime points are presented in Figures 7 and 8, 
respectively. At 1 year, spectra for both adults and children 
appear limited. The spectra at 2 years in the child appear 
normal, whereas the spectra at 3 years in the adult demon- 
strate residual skewing (in particular, V]313 B, -20, and -21). 
DISCUSSION 
Reconstitution of the circulating T-cell pool after mye- 
loablation and allogeneic SCT may occur following 2 dis- 
tinct mechanisms, both of which appear to play a role after 
UCBT in adults. The T-cell population in the months fol- 
lowing UCBT increased only slowly in absolute number, 
whereas the sjTREC concentration and T-cell proliferative 
responses to mitogens remained undetectable. At 1 year, 
T-cell repertoires were limited both in the number of VI3 
families represented and in the splicing diversity within fami- 
lies. These  findings are consistent with ant igen-dr iven 
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Figure 4. T-cell receptor excision circle (sjTREC) levels after umbilical cord blood transplantation for pediatric (D) (7 samples) and adult (0) 
(22 samples) recipients. Pediatric sjTREC value of 4615 copies/pg of peripheral blood mononuclear cell (PBMC) DNA at the 77-month follow-up 
was not plotted. Horizontal dashed lines represent estimated, age-adjusted normal sjTREC levels (based on median ages of 4.6 and 29.3 years for 
pediatric and adult recipients, respectively) [33]. 
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Figure 5. Complementarity-determining region 3 (CDR3) spectraty-ping for six adult umbilical cord blood transplant recipients 12 to 42 months 
after transplantation. Results are summarized as the number of peaks within each of 24 V[3 families (~1). UPIN indicates unique patient identifica- 
tion number. 
peripheral T-cell expansion occurring in the absence of 
thymic output. This analysis provides evidence that grafted 
UCB T-cells are able to respond to antigen stimulation and 
divide to begin to restore the circulating pool. The grafted 
T-cell pool is therefore vulnerable to repertoire skewing, 
presumably toward reactions against alloantigens, a factor 
that may exacerbate GVHD. Viral antigens may also drive 
expansion of the grafted T-ceU reservoir [9]. 
Starting 18 months after UCBT, sjTRECs were 
detectable in substantial (although lower than expected) lev- 
els in the peripheral blood of the adult patients. The detec- 
tion of sjTRECs coincided with the appearance of pheno- 
typically naive CD4 + T cells and improvement in 
proliferative responses to mitogens and recall antigen 
(tetanus). T-cell repertoires 3 years after transplantation 
appeared substantially more diverse in 3 of 4 patients, 
including 1 patient who had recovered from dramatic skew- 
ing. These findings support a second, thymic-dependent 
phase of T-celt reconstitution with attendant improvement 
in immunologic function and potential. 
In contrast to the adults studied, T-cell recovery in chil- 
dren, including naive CD4 § lymphocytes, occurred within 
6 to 12 months after UCBT. sjTRECs were detected in all 
pediatric patients as soon as 1 year after transplantation (the 
earliest time point tested). No child was tested prior to 1 year 
after transplantation, but other reports have documented 
thymic output in children at 100 days after transplantation, 
reaching apeak at 1 to 2 years [35]. T-cell repertoires from 2 
patients were diverse at 9 and 12 months and were normal in 
appearance in 2 more patients at 18 and 26 months. These 
findings indicate that the antigen-driven, peripheral expan- 
sion phase of T-cell reconstitution is short-lived in young 
patients. An early dominance of the thymus-dependent phase 
may prevent expansion of alloreactive T-cell clones and may 
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Figure 6. Complementarity-determining region3(CDR3) spectratyping for 6 pediatric umbilical cord blood transplant recipients 12 to 77 months 
after transplantation. Results are summarized as the number of peaks within each of 24 VI3 families ([]). UPIN indicates unique patient identifica- 
tion number. 
play a role in the reduced incidence of chronic GVHD in 
pediatric patients. The disparity between adult and pediatric 
patients in this study implicates host-specific or posttrans- 
plantation differences; however, it is important to note that 
the small number of children in the comparison cohort nec- 
essarily limits the strength of conclusions that can be drawn 
from this analysis. In addition, the selection of children for 
the comparison group--from patients returning to clinic-- 
may have introduced unexpected biases. 
A number of factors may have influenced the mechanism 
of T-cell recovery. First, thymic function declines with age 
[16,18,39], suggesting that reconstitutive potential declines 
with age. The thymuses of adult recipients may have natu- 
rally atrophied and/or been exposed to more therapy (or 
environmental oxins, etc.) before BMT than pediatric recip- 
ients, resulting in a delayed and attenuated response. The 
measured sjTREC levels in adult UCB recipients were lower 
than expected for normal controls based on median age. In 
contrast, a 3-fold higher sjTREC production has been docu- 
mented in patients aged 34 to 49 years who received mye- 
loablative chemotherapy for multiple myeloma followed by 
autologous stem cell rescne [40], confirming that adults can 
generate normal evels of sjTRECs after high-dose chemo- 
therapy. Peak thymic function may not yet have been 
reached in these adult UCB recipients at the times tested. 
The preparative regimen is unlikely to have played a 
confounding role. Adult and pediatric groups were matched 
in the exposure to TBI before transplantation, and both 
cohorts received melphalan or cyclophosphamide and ATG. 
In addition, posttransplantation supportive care (eg, growth 
factor support, antimicrobial prophylaxis) was the same for 
both groups. 
Despite the degree of HLA mismatch, the risk of 
GVHD following UCBT is lower than expected for hap- 
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ber of peaks appear within each family) but appears substantially normal at 3 years after transplantation. TCR indicates T-cell receptor. 
loidentical sibling allogeneic BMT [24]. Table 1 shows that 
the adult and pediatric ohorts were similarly matched for 
HLA disparity and incidence of acute GVHD. There was, 
however, a significant difference in the incidence of chronic 
GVHD. GVHD has long been known to be associated with 
delayed T-cell recovery [41] and thymic tissue injury [42], 
which may render the thymus unable to generate new T cells. 
sjTREC levels are lower than expected in allogeneic BMT 
patients with resolved GVHD and altogether absent in 
patients with active (chronic) GVHD [43]. Alternatively, 
medical prophylaxis to treat acute or chronic GVHD (CYA, 
FK506, or steroids) may injure the thymus, precursor T cells, 
or both. The adult and pediatric patients in this study dif- 
fered in the median duration of immunosuppression with 
CYA or FK506 (calculated for patients urviving at least 180 
days: 13 versus 7 months, respectively; P = .075). The recov- 
ery of TRECs was delayed in each adult, although chronic 
GVHD was documented in only 60%. This finding could be 
explained by residual thymic injury from prior (resolved) 
GVHD or by ongoing injury from subclinical chronic 
GVHD in the remaining 40%. 
These results may also have been observed if thymic 
function was be unaffected by transplantation, but the 
delivery of T-cell precursors from the bone marrow to the 
thymus was impaired. The infused mononuclear cell dose 
differed significantly between cohorts on a per-kilogram 
basis. The finite amount of fetal blood recoverable from 
any single postpartum placenta significantly limits the size 
of banked cord blood units. The weight of an adult UCBT 
recipient is a major l imitation to the infused cell dose 
(number of infused cells + weight of recipient) and likely 
accounts for the differences observed between groups. The 
difference in infused doses of CD34 § and CD3 + cells 
between cohorts did not reach significance, but variability 
in CD34 + and CD3 + content between cord blood units lim- 
ited the power to detect a difference. The differences in cell 
dose may have led to differences in the production of com- 
mon lymphoid progenitors from the grafts, which in turn 
would have led to reduced production of mature T cells. 
Notably, there was no significant difference in the time to 
absolute neutrophil count recovery or platelet ransfusion 
independence between cohorts, suggesting that the trans- 
planted grafts had similar capacity to differentiate at least 
some of the marrow precursors. 
It has been argued that sjTREC concentrations may not 
accurately reflect thymopoiesis, because the levels depend 
on the number of circulating PBMCs [44]. It is possible that 
ongoing activation of naive thymic emigrants and turnover 
of the T-cell pool as a whole diluted evidence of early 
thymic recovery in adult patients. In addition, the sjTREC 
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Figure 8. Fluorescence intensity spectra for each of 23 V[3 families (and 1 positive control) from a representative pediatric patient at 1 year (A) and 
2 years (B) after transplantation. The repertoire at 1 year demonstrates skewing, but it appears essentially normal at just 2 years after transplantation. 
The repertoire at 2 years appears more diverse than repertoires at3 years in adult patients (Figure 7). 
and CDR3 analyses were performed on unsorted, bulk 
mononuclear cell fractions. Differences between CD4 § and 
CD8 § T-cel l  populat ions will have been missed, and 
improvements in sjTREC counts and T-cell repertoires can- 
not be attributed to one population or the other. Future 
studies may be improved by measuring sjTREC levels and 
repertoire diversities within sorted lymphocyte subsets and 
by including markers of cellular activation, proliferation, 
and apoptosis in the phenotypic analyses. 
This report demonstrates the vital importance of pre- 
serving thymic function through myeloablative therapy and 
stem cell transplantation. UCB is prone to repertoire skew- 
ing, which may increase the risk of GVHD and may con- 
tribute to long-term immunoincompetence in the host. 
Infusions of mature, donor-derived T cells have been shown 
to improve T-cell repertoires, but they are not available to 
UCB recipients. Future investigations will need to focus on 
strategies to prevent GVHD while avoiding thymic injury. 
Cytoldne therapy may hold promise as a promoter of central 
T-cell maturation [39,45]. 
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